Clinical Trial: A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease

This study is no longer recruiting patients.

Sponsors and Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Glaxo Wellcome
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

To facilitate the use of zidovudine (AZT) in children who are 3 months to 12 years of age who are HIV-infected and either symptomatic or have a CD4 cell count < 400 cells/mm3 and to monitor adverse effects of AZT. Previous studies with pediatric patients have shown improvements in clinical, immunologic, and virologic parameters with administration of AZT.

Condition Treatment or Intervention
HIV Infections
 Drug: Zidovudine

MedlinePlus related topics:  AIDS

Study Type: Interventional
Study Design: Treatment

Further Study Details: 

Previous studies with pediatric patients have shown improvements in clinical, immunologic, and virologic parameters with administration of AZT.

This Treatment IND (investigational new drug) is an open label, uncontrolled protocol. AZT is ordered and prescribed by the patient's physician. The physician is responsible for obtaining informed consent, assuring that the patient meets the eligibility criteria, dispensing the medication to the patient, monitoring the patient's condition on treatment, and reporting required data to the project coordinating center.

Eligibility

Ages Eligible for Study:  3 Months   -   12 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Concurrent Treatment: Allowed:

  • Blood transfusions for hematologic toxicity.

Criteria for children 3 months to less than 15 months of age:

  • Patient must be HIV antibody-positive by repeated reactive screening test (e.g., ELISA) and positive confirmatory test (e.g., Western blot).

OR

  • If antibody-negative, patient must have two positive p24 antigen determinations performed at least one week apart or have had a positive HIV culture.

Patients must meet two of the following criteria:

  • Be HIV culture positive or p24 antigen positive.
  • Have at least one of the Class P-2 symptoms (by CDC criteria).

Be immunosuppressed defined as having:

  • CD4+(T4) lymphocytes = or < 400 cells/mm3.
  • Abnormal age adjusted immunoglobulin levels (IgG or IgA). Decreased helper/suppressor ratio < 1.0.

Note:

  • In general, abnormal values for any of the above lab tests should be confirmed in 2 measurements at least 1 week apart, and other clinical causes for these abnormalities should be ruled out.

Criteria for children 15 months to 12 years of age:

  • Patient must be HIV antibody-positive by repeated reactive screening test (e.g., ELISA) and positive confirmatory test (e.g., Western blot).

OR

  • If antibody-negative, patient must have two positive p24 antigen determinations performed at least one week apart or have had a positive HIV culture.

Patients must meet one of the following criteria:

  • Have at least one of the class P-2 symptoms (by CDC criteria).
  • Be immunosuppressed defined as having CD4+(T4) lymphocytes = or < 400 cells/mm3, based on two measurements at least 1 week apart.

Exclusion Criteria

Co-existing Condition: Patients with known hypersensitivity to AZT are excluded.

Patients with the following are excluded:


Location Information


North Carolina
      Glaxo Wellcome Inc, Research Triangle Park,  North Carolina,  27709,  United States

More Information

Click here for more information about Zidovudine

Study ID Numbers:  TX 304; FDA 43A
Record last reviewed:  April 1992
Last Updated:  April 7, 2005
Record first received:  November 2, 1999
ClinicalTrials.gov Identifier:  NCT00000662
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08


Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Resources